SI1454992T1 - Test kinaze anaplasticnega limfoma, reagenti in sestavki le-teh - Google Patents
Test kinaze anaplasticnega limfoma, reagenti in sestavki le-tehInfo
- Publication number
- SI1454992T1 SI1454992T1 SI200330308T SI200330308T SI1454992T1 SI 1454992 T1 SI1454992 T1 SI 1454992T1 SI 200330308 T SI200330308 T SI 200330308T SI 200330308 T SI200330308 T SI 200330308T SI 1454992 T1 SI1454992 T1 SI 1454992T1
- Authority
- SI
- Slovenia
- Prior art keywords
- reagents
- compositions
- kinase assay
- anaplastic lymphoma
- lymphoma kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03005186A EP1454992B1 (en) | 2003-03-07 | 2003-03-07 | Anaplastic lymphoma kinase assay, reagents and compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1454992T1 true SI1454992T1 (sl) | 2006-10-31 |
Family
ID=32798804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200330308T SI1454992T1 (sl) | 2003-03-07 | 2003-03-07 | Test kinaze anaplasticnega limfoma, reagenti in sestavki le-teh |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070031907A1 (sl) |
EP (1) | EP1454992B1 (sl) |
JP (1) | JP2006519800A (sl) |
CN (1) | CN100345978C (sl) |
AT (1) | ATE328112T1 (sl) |
CA (1) | CA2518094A1 (sl) |
CY (1) | CY1106115T1 (sl) |
DE (1) | DE60305634T2 (sl) |
DK (1) | DK1454992T3 (sl) |
ES (1) | ES2263862T3 (sl) |
HK (1) | HK1068154A1 (sl) |
IL (1) | IL170669A0 (sl) |
PT (1) | PT1454992E (sl) |
SI (1) | SI1454992T1 (sl) |
WO (1) | WO2004079326A2 (sl) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
DK2447359T3 (en) | 2006-04-14 | 2016-02-08 | Cell Signaling Technology Inc | Genetic defects and mutated ALK kinase in human solid tumors |
EP2107054A1 (en) | 2008-04-01 | 2009-10-07 | Università Degli Studi Di Milano - Bicocca | Antiproliferative compounds and therapeutic uses thereof |
EP2274288A2 (en) | 2008-04-24 | 2011-01-19 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
EP2161271A1 (en) | 2008-09-08 | 2010-03-10 | Università Degli Studi Di Milano - Bicocca | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl |
WO2010085597A1 (en) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
NZ597477A (en) | 2009-06-10 | 2014-03-28 | Chugai Pharmaceutical Co Ltd | Tetracyclic compounds |
CN101955995B (zh) * | 2010-06-17 | 2013-06-26 | 江苏迈迪基因生物科技有限公司 | 淋巴瘤相关的融合基因的诊断试剂盒 |
WO2012019132A2 (en) * | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
CN103052386B (zh) | 2010-08-20 | 2016-03-02 | 中外制药株式会社 | 含有四环化合物的组合物 |
ES2905448T3 (es) | 2012-05-10 | 2022-04-08 | Massachusetts Gen Hospital | Métodos para determinar una secuencia nucleotídica |
HUE040055T2 (hu) | 2012-09-25 | 2019-02-28 | Chugai Pharmaceutical Co Ltd | RET inhibitor |
CN104994879A (zh) | 2013-02-22 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 治疗癌症和预防药物抗性的方法 |
EP4219744A3 (en) | 2014-01-27 | 2023-08-30 | The General Hospital Corporation | Methods of preparing nucleic acids for sequencing |
CA2946518C (en) | 2014-04-25 | 2022-07-26 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
CN106458967A (zh) | 2014-04-25 | 2017-02-22 | 中外制药株式会社 | 四环化合物的新结晶 |
TWI803187B (zh) | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含4環性化合物的非晶質體之固體分散體及製劑 |
EP3246047A4 (en) | 2015-01-16 | 2018-08-22 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
WO2018053365A1 (en) | 2016-09-15 | 2018-03-22 | ArcherDX, Inc. | Methods of nucleic acid sample preparation for analysis of cell-free dna |
WO2018053362A1 (en) | 2016-09-15 | 2018-03-22 | ArcherDX, Inc. | Methods of nucleic acid sample preparation |
CN110191959B (zh) | 2016-11-02 | 2024-04-09 | 阿谢尔德克斯有限责任公司 | 用于免疫组库测序的核酸样品制备方法 |
SG11202100983XA (en) | 2018-09-04 | 2021-03-30 | Chugai Pharmaceutical Co Ltd | Method of producing tetracyclic compound |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05126833A (ja) * | 1991-10-31 | 1993-05-21 | Tosoh Corp | チロシンキナ−ゼ活性の免疫化学的測定法及びそのキツト |
CA2117913C (en) * | 1992-04-10 | 2006-05-09 | Richard J. Epstein | Activation-state-specific phosphoprotein immunodetection |
US5344926A (en) * | 1992-06-22 | 1994-09-06 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing staurosporine derivatives |
GB9314271D0 (en) * | 1993-07-09 | 1993-08-18 | Inst Of Cancer The Research | Cell growth factor receptors |
US6001621A (en) * | 1993-11-23 | 1999-12-14 | Genetech, Inc. | Protein tyrosine kinases |
CA2175892C (en) * | 1993-11-23 | 2000-03-07 | Paul J. Godowski | Kinase receptor activation assay |
US5529925A (en) * | 1993-12-03 | 1996-06-25 | St. Jude Children's Research Hospital | Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma |
US5763198A (en) * | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
US5759787A (en) * | 1996-08-26 | 1998-06-02 | Tularik Inc. | Kinase assay |
EP0979288A2 (en) * | 1997-04-28 | 2000-02-16 | Sugen, Inc. | Diagnosis and treatment of phosphatase- or kinase-related disorders |
EP1201668A4 (en) * | 1999-07-13 | 2003-05-21 | Kyowa Hakko Kogyo Kk | STAUROSPORINE DERIVATIVES |
-
2003
- 2003-03-07 ES ES03005186T patent/ES2263862T3/es not_active Expired - Lifetime
- 2003-03-07 PT PT03005186T patent/PT1454992E/pt unknown
- 2003-03-07 AT AT03005186T patent/ATE328112T1/de not_active IP Right Cessation
- 2003-03-07 DK DK03005186T patent/DK1454992T3/da active
- 2003-03-07 SI SI200330308T patent/SI1454992T1/sl unknown
- 2003-03-07 EP EP03005186A patent/EP1454992B1/en not_active Expired - Lifetime
- 2003-03-07 DE DE60305634T patent/DE60305634T2/de not_active Expired - Fee Related
-
2004
- 2004-03-04 JP JP2006504533A patent/JP2006519800A/ja active Pending
- 2004-03-04 CN CNB2004800060187A patent/CN100345978C/zh not_active Expired - Fee Related
- 2004-03-04 CA CA002518094A patent/CA2518094A1/en not_active Abandoned
- 2004-03-04 US US10/547,842 patent/US20070031907A1/en not_active Abandoned
- 2004-03-04 WO PCT/EP2004/002185 patent/WO2004079326A2/en active Application Filing
-
2005
- 2005-02-17 HK HK05101314A patent/HK1068154A1/xx not_active IP Right Cessation
- 2005-09-05 IL IL170669A patent/IL170669A0/en unknown
-
2006
- 2006-07-04 CY CY20061100923T patent/CY1106115T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN1756850A (zh) | 2006-04-05 |
WO2004079326A2 (en) | 2004-09-16 |
IL170669A0 (en) | 2011-08-01 |
PT1454992E (pt) | 2006-09-29 |
CA2518094A1 (en) | 2004-09-16 |
WO2004079326A3 (en) | 2004-12-09 |
US20070031907A1 (en) | 2007-02-08 |
CY1106115T1 (el) | 2011-06-08 |
JP2006519800A (ja) | 2006-08-31 |
DE60305634D1 (de) | 2006-07-06 |
CN100345978C (zh) | 2007-10-31 |
DK1454992T3 (da) | 2006-10-02 |
ATE328112T1 (de) | 2006-06-15 |
EP1454992B1 (en) | 2006-05-31 |
DE60305634T2 (de) | 2006-09-21 |
ES2263862T3 (es) | 2006-12-16 |
HK1068154A1 (en) | 2005-04-22 |
EP1454992A1 (en) | 2004-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL170669A0 (en) | Anaplastic lymphoma kinase assay, reagents and compositions thereof | |
WO2005111212A3 (en) | Biological bar code | |
WO2003029262A3 (en) | The human mob-5 (il-24) receptors and uses thereof | |
WO2005012574A3 (en) | Biological bar-code | |
WO2003000853A3 (en) | Protein aggregation assays and uses thereof | |
AU2003278725A8 (en) | Polynucleotide predictor set for identifying protein tyrosine kinase modulators | |
WO2004020458A3 (en) | Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents | |
DE60007095T2 (de) | Calanolide zur hemmung von btk | |
EP1700120A4 (en) | MARKER FOR OPTICAL NEUROMYELITIS | |
WO2002047535A3 (en) | High throughput assay to detect inhibitors of the map kinase pathway | |
HK1080074A1 (zh) | 作為酪氨酸蛋白激酶抑制劑的4,6-二氨基取代-2-[氧基或氨氧基]-[1,3,5]三嗪 | |
EP1395275A4 (en) | BETA SECRETASE SUBSTRATES AND THEIR USE | |
WO2004050842A3 (en) | Atm kinase compositions and methods | |
WO2002053743A3 (en) | Mammalian tribbles signaling pathways and methods and reagents related thereto | |
WO2001096604A3 (en) | Assay for genetic polymorphisms using scattered light detectable labels | |
WO2007033374A3 (en) | Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor | |
MXPA05001690A (es) | Estrategia de deteccion para farmacos anticancer. | |
DK1224222T3 (da) | Chemokinreceptor | |
AU2002212133A1 (en) | Process for detecting serine/threonine kinase activity | |
WO2005037859A3 (en) | Fluorescence assay for kinase activity | |
WO2005003388A3 (en) | Fluorescence assays for nucleic acid polymerase activity | |
WO2005037231A3 (en) | Methods of detecting and treating facioscapulohumeral muscular dystrophy | |
WO2003014324A3 (en) | Thermostable uvra and uvrb polipeptides and methods of use | |
WO2001012838A3 (en) | Compounds which modulate the activity of an lpa receptor | |
DE60329931D1 (de) | Fprl1-liganden und deren verwendung |